On March 16, 2021 Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, reported that the United States Patent and Trademark Office has issued U.S. Patent No. 10,945,954 entitled "ARRDC1-Mediated Microvesicles (ARMMs) and Uses Thereof (Press release, Vesigen Therapeutics, MAR 16, 2021, View Source [SID1234576751])". This patent, exclusively licensed to Vesigen from Harvard University, broadly covers many of the drug delivery features of any ARRDC1-mediated microvesicles (ARMMs).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This patent covers ARMMs compositions containing an enzymatic payload. Important enzymes include those needed in enzyme replacement therapy as well as those intended to create a therapeutic function.
"The issuance of this patent has strengthened Vesigen’s intellectual property estate and provided us with a vast therapeutic blueprint to enable a robust pipeline of agents for use in CNS, oncology, ocular applications and beyond," said Robert Millman, Co-Founder and CEO of Vesigen Therapeutics.
ARMMs particles are a unique class of extracellular vesicles that are naturally produced by cells and serve as a vehicle to package and deliver communication signals, including transcription complexes, between cells and tissues. ARMMs show enhanced functionality in packaging and transferring payloads, by fusing directly with the cell membrane of a target cell. The cellular ARRDC1 system is a pathway co-opted by enveloped viruses, such as HIV, using a functional homolog, Gag. Like ARMMs particles, enveloped virus particles avoid immune clearance and deliver their viral genome payload specifically to target cells in a fusogenic delivery. Vesigen is engineering ARMMs particles to improve this natural mechanism for more effective targeted delivery of therapeutic agents.